Usage: Carbidopa, levodopa, and entacapone tablets are indicated for treating Parkinson’s disease. They can substitute individual components of carbidopa/levodopa and entacapone or replace carbidopa/levodopa therapy when patients experience end-of-dose “wearing-off” symptoms and have not exceeded a daily levodopa dose of 600 mg.